Mallinckrodt PLC (MNK) is Broadwood Capital Inc.’s 6th Largest Position
Broadwood Capital Inc. boosted its holdings in Mallinckrodt PLC (NYSE:MNK) by 100.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 644,822 shares of the company’s stock after buying an additional 322,411 shares during the period. Mallinckrodt accounts for approximately 4.0% of Broadwood Capital Inc.’s holdings, making the stock its 6th largest holding. Broadwood Capital Inc. owned approximately 0.68% of Mallinckrodt worth $24,097,000 as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Sterling Capital Management LLC acquired a new position in shares of Mallinckrodt in the 2nd quarter valued at about $204,000. Advisor Partners LLC acquired a new position in shares of Mallinckrodt in the 2nd quarter valued at about $242,000. Municipal Employees Retirement System of Michigan lifted its stake in shares of Mallinckrodt by 24.5% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 5,640 shares of the company’s stock valued at $253,000 after purchasing an additional 1,110 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new position in shares of Mallinckrodt in the 2nd quarter valued at about $260,000. Finally, Alps Advisors Inc. lifted its stake in shares of Mallinckrodt by 22.3% in the 2nd quarter. Alps Advisors Inc. now owns 6,465 shares of the company’s stock valued at $290,000 after purchasing an additional 1,179 shares in the last quarter. 97.40% of the stock is currently owned by hedge funds and other institutional investors.
Mallinckrodt PLC (NYSE MNK) traded down $0.38 during mid-day trading on Thursday, reaching $21.35. The company’s stock had a trading volume of 2,031,500 shares, compared to its average volume of 2,582,575. The company has a quick ratio of 1.05, a current ratio of 1.38 and a debt-to-equity ratio of 1.08. Mallinckrodt PLC has a 52 week low of $19.00 and a 52 week high of $55.32. The stock has a market cap of $2,064.46, a P/E ratio of 2.93, a PEG ratio of 0.39 and a beta of 1.30.
In other Mallinckrodt news, General Counsel Michael-Bryant Hicks acquired 7,900 shares of the company’s stock in a transaction on Thursday, November 9th. The shares were bought at an average cost of $20.80 per share, for a total transaction of $164,320.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director David R. Carlucci acquired 10,000 shares of the company’s stock in a transaction on Thursday, November 9th. The shares were acquired at an average price of $21.83 per share, for a total transaction of $218,300.00. Following the completion of the acquisition, the director now directly owns 26,020 shares in the company, valued at $568,016.60. The disclosure for this purchase can be found here. Insiders have acquired a total of 30,460 shares of company stock worth $659,486 over the last 90 days. 0.77% of the stock is owned by company insiders.
Several equities analysts have recently weighed in on MNK shares. UBS set a $70.00 price objective on Mallinckrodt and gave the company a “buy” rating in a research note on Wednesday, August 9th. Deutsche Bank set a $56.00 price objective on Mallinckrodt and gave the company a “buy” rating in a research note on Wednesday, August 9th. Raymond James Financial reduced their price objective on Mallinckrodt from $65.00 to $58.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 9th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $65.00 price objective (down from $69.00) on shares of Mallinckrodt in a research note on Wednesday, August 9th. Finally, Mizuho reaffirmed a “buy” rating and issued a $70.00 price objective (down from $73.00) on shares of Mallinckrodt in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $48.14.
COPYRIGHT VIOLATION WARNING: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/12/07/mallinckrodt-plc-mnk-is-broadwood-capital-inc-s-6th-largest-position.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Stock Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related stocks with our FREE daily email newsletter.